Last reviewed · How we verify

Orasis Pharmaceuticals Ltd. — Portfolio Competitive Intelligence Brief

Orasis Pharmaceuticals Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
CSF-1 CSF-1 phase 3 Cytokine CSF-1 receptor (c-FMS) Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amgen · 1 shared drug class
  2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  3. Centre for Endocrinology and Reproductive Medicine, Italy · 1 shared drug class
  4. King's College London · 1 shared drug class
  5. Radboud University Medical Center · 1 shared drug class
  6. Sandoz · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Orasis Pharmaceuticals Ltd.:

Cite this brief

Drug Landscape (2026). Orasis Pharmaceuticals Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/orasis-pharmaceuticals-ltd. Accessed 2026-06-10.

Related